Browse News

Found 82 articles

• Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

  5/15/2022

  Zenas BioPharma announced the submission of an investigational new drug application to the China National Medical Products Administration for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease.

• Viridian Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates

  5/12/2022

  Viridian Therapeutics, Inc. announced financial results for the first quarter ending March 31, 2022 and provided corporate updates, including interim results for the healthy volunteer portion of the Company’s ongoing proof of concept trial of VRDN-001 in Thyroid Eye Disease.

• Dianthus Therapeutics Launches with $100M to Develop Selective Antibody Complement Therapeutics to Treat Severe and Rare Autoimmune Diseases

  5/3/2022

  Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today announced the completion of its $100 million Series A financing.

• Viridian Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 12, 2022

  5/3/2022

  Viridian Therapeutics, Inc. today announced it will report its financial results from the first quarter ended March 31, 2022, after the financial markets close on Thursday, May 12, 2022.

• Akerna to Announce Financial Results for the First Quarter of 2022 on May 9, 2022

  4/27/2022

  Akerna (Nasdaq: KERN), a leading enterprise software company and developer of one of the most comprehensive technology infrastructures, ecosystems, and compliance engines powering the global cannabis industry, today announces that management will report its financial results for the first quarter ended March 31, 2022, after the close of trading on Monday, May 9, 2022. 

• Viridian Therapeutics to Participate in The 21st Annual Needham Virtual Healthcare Conference on April 14

  4/6/2022

  Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer will participate in the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, which includes a presentation beginning at 4:30 p.m. ET.

• Viridian Therapeutics Secures Flexible Credit Facility for Up to $75 Million From Hercules Capital

  4/4/2022

  Viridian Therapeutics, Inc. announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. for up to $75 million.

• Akerna Announces Fourth Quarter and Full Year 2021 Financial Results

  3/21/2022

  Akerna today reported its unaudited financial results for the quarter and year ended December 31, 2021.

• Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

  3/21/2022

  Viridian Therapeutics, Inc. announced that it has dosed the first subject in a Phase 1 clinical trial evaluating VRDN-002 for the treatment of thyroid eye disease.

• Viridian Therapeutics to Participate in 32nd Annual Oppenheimer Healthcare Conference on March 15

  3/14/2022

  Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on March 15, 2022.

• Viridian Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Updates

  3/10/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided corporate updates.

• Akerna to Announce Financial Results for the Fourth Quarter and Full Year 2021 on March 21, 2022

  3/8/2022

  Akerna (Nasdaq: KERN), a leading enterprise software company and developer of the most comprehensive technology infrastructure, ecosystem, and compliance engine powering the global cannabis industry, today announces that management will report its financial results for the fourth quarter and full year ended December 31, 2021.

• Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022

  3/3/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2021, after the financial markets close on Thursday, March 10, 2022.

• TC Biopharm Announces Appointment of New Board Members

  2/22/2022

  TC Biopharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, is pleased to announce the appointment of 4 new members to its Board of Directors.

• Viridian Therapeutics to Participate in the SVB Leerink 2022 Global Healthcare Conference on February 18

  2/14/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer will participate in a Fireside Chat at the SVB Leerink 11th Annual Global Healthcare Conference.

• Ensysce Biosciences Appoints Industry Veteran Lee Rauch to Board of Directors

  2/8/2022

  Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), today announced that Lee Rauch has been appointed to the Company’s board of directors.

• Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease

  1/31/2022

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the United States Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application of VRDN-002.

• 

  Clinical Catch-Up: January 3-7

  1/10/2022

  The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look.

• Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

  1/4/2022

  Viridian Therapeutics, Inc. announced the submission of an investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for VRDN-002, a humanized monoclonal antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection for the treatment of thyroid eye disease (TED).

• Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

  12/20/2021

  Viridian Therapeutics, Inc. today announced the first subject was dosed in a Phase 1/2 proof-of-concept clinical trial for VRDN-001.